CN115052615A - 肽缀合物和使用方法 - Google Patents
肽缀合物和使用方法 Download PDFInfo
- Publication number
- CN115052615A CN115052615A CN202080095675.2A CN202080095675A CN115052615A CN 115052615 A CN115052615 A CN 115052615A CN 202080095675 A CN202080095675 A CN 202080095675A CN 115052615 A CN115052615 A CN 115052615A
- Authority
- CN
- China
- Prior art keywords
- peptide
- seq
- receptor
- conjugate
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962943667P | 2019-12-04 | 2019-12-04 | |
| US62/943,667 | 2019-12-04 | ||
| US202062994791P | 2020-03-25 | 2020-03-25 | |
| US62/994,791 | 2020-03-25 | ||
| PCT/US2020/063149 WO2021113535A1 (en) | 2019-12-04 | 2020-12-03 | Peptide conjugates and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN115052615A true CN115052615A (zh) | 2022-09-13 |
Family
ID=76222285
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080095675.2A Pending CN115052615A (zh) | 2019-12-04 | 2020-12-03 | 肽缀合物和使用方法 |
| CN202080095661.0A Active CN115052886B (zh) | 2019-12-04 | 2020-12-03 | Glp2受体激动剂和使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080095661.0A Active CN115052886B (zh) | 2019-12-04 | 2020-12-03 | Glp2受体激动剂和使用方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20230057847A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4069726A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7834640B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20220110244A (cg-RX-API-DMAC7.html) |
| CN (2) | CN115052615A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020397917A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA3163522A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL293522A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022006732A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2021113524A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025073222A1 (zh) * | 2023-10-07 | 2025-04-10 | 深圳湾实验室 | Glp-1r/gipr/gcgr三重激动剂类似物及其用途 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10039809B2 (en) | 2013-12-18 | 2018-08-07 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| EP4069726A4 (en) * | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | GLP2 RECEPTOR AGONISTS AND METHOD OF USE |
| CN118754965A (zh) | 2020-05-29 | 2024-10-11 | 北京拓界生物医药科技有限公司 | Glp-1和gip受体双重激动剂化合物及其应用 |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
| CN116970063A (zh) * | 2022-04-29 | 2023-10-31 | 苏州星洲生物科技有限公司 | Glp-1/gip受体共激动剂、包含其的药物组合物及其用途 |
| CN114949183B (zh) * | 2022-05-07 | 2023-02-28 | 山东京卫制药有限公司 | 一种替尔泊肽粉雾剂及其制备方法 |
| US20260124278A1 (en) * | 2022-05-27 | 2026-05-07 | D&D Pharmatech Inc. | Compositions and methods for treatment of neurological disorders |
| AR131430A1 (es) * | 2022-12-21 | 2025-03-19 | Boehringer Ingelheim Int | Agonistas triples de los receptores de glp1 / gip / npy2 |
| WO2024153090A1 (zh) * | 2023-01-17 | 2024-07-25 | 广东众生睿创生物科技有限公司 | 基于glp-1的三重激动剂 |
| WO2025184552A2 (en) * | 2024-03-01 | 2025-09-04 | The Scripps Research Institute | Dual gip/glp-1 peptide conjugates and methods of use |
| WO2025217640A1 (en) * | 2024-04-12 | 2025-10-16 | Eli Lilly And Company | Compositions and methods for treating metabolic diseases |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252916A1 (en) * | 2002-06-04 | 2006-11-09 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| US20160317623A1 (en) * | 2013-12-18 | 2016-11-03 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| US20170260248A1 (en) * | 2010-07-09 | 2017-09-14 | Dana-Farber Cancer Institute, Inc. | Stabilized insulinotropic peptides and methods of use |
| CN107921098A (zh) * | 2015-06-17 | 2018-04-17 | 加州生物医学研究所 | 修饰的治疗剂及其组合物 |
| CN110036022A (zh) * | 2016-10-27 | 2019-07-19 | 詹森药业有限公司 | 作为神经肽y受体的调节剂的抗体-偶联的环状肽酪氨酸酪氨酸化合物 |
| WO2019207505A1 (en) * | 2018-04-25 | 2019-10-31 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
Family Cites Families (121)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3887699A (en) | 1969-03-24 | 1975-06-03 | Seymour Yolles | Biodegradable polymeric article for dispensing drugs |
| US3854480A (en) | 1969-04-01 | 1974-12-17 | Alza Corp | Drug-delivery system |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| PH19942A (en) | 1980-11-18 | 1986-08-14 | Sintex Inc | Microencapsulation of water soluble polypeptides |
| US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| DE3218121A1 (de) | 1982-05-14 | 1983-11-17 | Leskovar, Peter, Dr.-Ing., 8000 München | Arzneimittel zur tumorbehandlung |
| US4452775A (en) | 1982-12-03 | 1984-06-05 | Syntex (U.S.A.) Inc. | Cholesterol matrix delivery system for sustained release of macromolecules |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US5133974A (en) | 1989-05-05 | 1992-07-28 | Kv Pharmaceutical Company | Extended release pharmaceutical formulations |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
| US5470582A (en) | 1992-02-07 | 1995-11-28 | Syntex (U.S.A.) Inc. | Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles |
| JPH08503950A (ja) | 1992-12-02 | 1996-04-30 | アルカーメス・コントロールド・セラピユーテイクス・インコーポレーテツド | 徐放性成長ホルモン含有マイクロスフェア |
| CA2165781C (en) | 1993-06-21 | 2007-02-13 | Tim Breece | Process for producing relaxin |
| US6011007A (en) | 1993-09-17 | 2000-01-04 | Novo Nordisk A/S | Acylated insulin |
| US6869930B1 (en) | 1993-09-17 | 2005-03-22 | Novo Nordisk A/S | Acylated insulin |
| NZ273285A (en) | 1993-09-17 | 1997-10-24 | Novo Nordisk As | Insulin derivatives and compositions thereof |
| US6372716B1 (en) | 1994-04-26 | 2002-04-16 | Genetics Institute, Inc. | Formulations for factor IX |
| EP1002529A1 (en) | 1994-09-09 | 2000-05-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation containing a metal salt of a peptide |
| ES2170853T3 (es) | 1995-03-28 | 2002-08-16 | Fidia Advanced Biopolymers Srl | Nanosferas que comprenden un polisacarido biocompatible. |
| US6184201B1 (en) | 1995-04-14 | 2001-02-06 | Nps Allelix Corp. | Intestinotrophic glucagon-like peptide-2 analogs |
| TW457240B (en) | 1995-04-20 | 2001-10-01 | Janssen Pharmaceutica Nv | Novel triazolones as apolipoprotein-B synthesis inhibitors |
| US5911997A (en) | 1995-06-07 | 1999-06-15 | Connetics Corporation | Relaxin-like factor and methods and uses thereof |
| SK281571B6 (sk) | 1995-06-07 | 2001-05-10 | Alkermes Controlled Therapeutics, Inc. | Prostriedok na trvalé uvoľňovanie ľudského rastového hormónu |
| US5811395A (en) | 1995-06-07 | 1998-09-22 | Medical University Of South Carolina | Relaxin analogs and derivatives methods and uses thereof |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5736152A (en) | 1995-10-27 | 1998-04-07 | Atrix Laboratories, Inc. | Non-polymeric sustained release delivery system |
| US5612051A (en) | 1995-11-17 | 1997-03-18 | Yue; Samuel K. | Method of treating involuntary muscle dysfunction with relaxin hormone |
| US5866538A (en) | 1996-06-20 | 1999-02-02 | Novo Nordisk A/S | Insulin preparations containing NaCl |
| US6268343B1 (en) | 1996-08-30 | 2001-07-31 | Novo Nordisk A/S | Derivatives of GLP-1 analogs |
| US6444641B1 (en) | 1997-10-24 | 2002-09-03 | Eli Lilly Company | Fatty acid-acylated insulin analogs |
| ZA989744B (en) | 1997-10-31 | 2000-04-26 | Lilly Co Eli | Method for administering acylated insulin. |
| DE19822820A1 (de) | 1998-05-20 | 1999-11-25 | Biotechnolog Forschung Gmbh | Pharmazeutisches Präparat zur Wundbehandlung |
| US6566329B1 (en) | 1999-06-28 | 2003-05-20 | Novo Nordisk A/S | Freeze-dried preparation of human growth hormone |
| KR20030097876A (ko) | 2001-05-21 | 2003-12-31 | 넥타르 테라퓨틱스 | 화학적으로 개질된 인슐린의 폐 투여 |
| AU2003243316A1 (en) | 2002-05-24 | 2003-12-12 | Nps Allelix Corp. | Method for enzymatic production of glp-2(1-33) and glp-2-(1-34) peptides |
| US20050176108A1 (en) | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
| CN1849141A (zh) | 2003-05-12 | 2006-10-18 | 阿费麦克斯公司 | 用于聚(乙二醇)修饰的肽的间隔臂部分 |
| US20060183667A1 (en) | 2003-07-11 | 2006-08-17 | Novo Nordisk A/S | Stabilised insulin compositions |
| EP1670515A2 (en) | 2003-09-19 | 2006-06-21 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| WO2005118620A2 (en) | 2004-05-27 | 2005-12-15 | New York University | Methods for preparing internally constraied peptides and peptidomimetics |
| US20090054623A1 (en) | 2004-12-17 | 2009-02-26 | Neose Technologies, Inc. | Lipo-Conjugation of Peptides |
| TWI362392B (en) | 2005-03-18 | 2012-04-21 | Novo Nordisk As | Acylated glp-1 compounds |
| DE602006020123D1 (de) | 2005-05-04 | 2011-03-31 | Zealand Pharma As | Glucagon-like-peptide-2- (glp-2-) analoga |
| AU2006321743A1 (en) | 2005-10-24 | 2007-06-14 | Centocor, Inc. | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
| EP2471810A1 (en) | 2006-02-22 | 2012-07-04 | Merck Sharp & Dohme Corporation | Oxyntomodulin derivatives |
| US20080305519A1 (en) | 2006-02-23 | 2008-12-11 | Qing Lin | Biochemical method for specific protein labeling |
| US7790847B2 (en) | 2006-03-16 | 2010-09-07 | The Scripps Research Institute | Genetically programmed expression of proteins containing the unnatural amino acid phenylselenocysteine |
| US20070244048A1 (en) | 2006-03-20 | 2007-10-18 | Marsh Donald J | Neuromedin U receptor agonists and uses thereof |
| AU2007227202B2 (en) | 2006-03-21 | 2013-08-22 | Amylin Pharmaceuticals, Llc | Peptide-peptidase inhibitor conjugates and methods of using same |
| EP2007804B1 (en) | 2006-04-20 | 2014-06-18 | Amgen, Inc | Glp-1 compounds |
| MX2008015107A (es) | 2006-05-26 | 2008-12-09 | Amylin Pharmaceuticals Inc | Composicion y metodos para el tratamiento de insuficiecia cardiaca congestiva. |
| US7812121B2 (en) | 2006-08-31 | 2010-10-12 | Baker Audrey E | GLP-2 mimetibodies, polypeptides, compositions, methods and uses |
| WO2008037735A1 (en) | 2006-09-27 | 2008-04-03 | Novo Nordisk A/S | Method for making maturated insulin polypeptides |
| KR20090091145A (ko) | 2006-10-27 | 2009-08-26 | 웨이-치앙 션 | 지질화된 인터페론 및 이의 용도 |
| CA2686827C (en) | 2006-12-14 | 2014-09-16 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| US7981998B2 (en) | 2006-12-14 | 2011-07-19 | Aileron Therapeutics, Inc. | Bis-sulfhydryl macrocyclization systems |
| NZ578948A (en) | 2007-02-15 | 2012-03-30 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists |
| CN109627287A (zh) | 2007-02-23 | 2019-04-16 | 爱勒让治疗公司 | 三唑大环系统 |
| US8420598B2 (en) | 2007-04-20 | 2013-04-16 | B & L Delipharm Corp. | Mono modified exendin with polyethylene glycol or its derivatives and uses thereof |
| AU2008266753A1 (en) | 2007-06-20 | 2008-12-24 | Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. | ApoA-1 peptide mimetics |
| BRPI0907754A2 (pt) | 2008-02-08 | 2015-07-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos terapêuticos |
| US20110144303A1 (en) | 2008-04-08 | 2011-06-16 | Aileron Therapeutics, Inc. | Biologically Active Peptidomimetic Macrocycles |
| US20090326192A1 (en) | 2008-04-08 | 2009-12-31 | Aileron Therapeutics, Inc. | Biologically active peptidomimetic macrocycles |
| ES2558842T3 (es) | 2008-06-17 | 2016-02-09 | Indiana University Research And Technology Corporation | Agonistas mixtos a base de GIP para el tratamiento de trastornos metabólicos y obesidad |
| US8586707B2 (en) | 2008-09-16 | 2013-11-19 | The Research Foundation Of State University Of New York | Stapled peptides and method of synthesis |
| CN102884074A (zh) | 2008-09-22 | 2013-01-16 | 爱勒让治疗公司 | 拟肽大环化合物 |
| CN102203126A (zh) | 2008-09-22 | 2011-09-28 | 爱勒让治疗公司 | 用于制备纯化的多肽组合物的方法 |
| US8524653B2 (en) | 2008-09-22 | 2013-09-03 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| WO2010060112A1 (en) | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| EP2376100B1 (en) | 2009-01-14 | 2017-10-25 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| JP6054742B2 (ja) | 2009-07-13 | 2016-12-27 | ジーランド ファーマ アクティーゼルスカブ | アシル化グルカゴン類似体 |
| KR20120092611A (ko) | 2009-09-30 | 2012-08-21 | 글락소 그룹 리미티드 | 연장된 반감기를 갖는 약물 융합체 및 컨쥬게이트 |
| BR112012008831A2 (pt) | 2009-10-14 | 2019-09-24 | Aileron Therapeutics Inc | macrociclos de peptideomiméticos aprimorados. |
| US20120329711A1 (en) | 2009-12-16 | 2012-12-27 | Nordisk A/S | Glp-1 receptor agonist compounds with a modified n-terminus |
| WO2011075393A2 (en) | 2009-12-18 | 2011-06-23 | Indiana University Research And Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US20110245469A1 (en) | 2010-04-02 | 2011-10-06 | Athena Discovery, Inc. | Intermediates formed in biosynthesis of relaxin-fusion proteins with extended in vivo half-lives |
| AU2011276109A1 (en) | 2010-07-09 | 2013-01-24 | Jv Bio Srl | Lipid-conjugated antibodies |
| WO2012012352A2 (en) | 2010-07-19 | 2012-01-26 | Amidebio, Llc | Modified peptides and proteins |
| KR101382593B1 (ko) | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
| PE20140160A1 (es) | 2010-08-17 | 2014-02-08 | Ambrx Inc | Polipeptidos de relaxina modificados y sus usos |
| US9567386B2 (en) | 2010-08-17 | 2017-02-14 | Ambrx, Inc. | Therapeutic uses of modified relaxin polypeptides |
| US9029332B2 (en) | 2010-12-15 | 2015-05-12 | The Research Foundation For The State University Of New York | Cross-linked peptides and proteins, methods of making same, and uses thereof |
| NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| RU2013133803A (ru) | 2010-12-22 | 2015-01-27 | Маркадиа Байотек, Инк. | Способы лечения метаболических нарушений и ожирения при помощи пептидов на основе глюкагона, активных по отношению к рецепторам гип и гпп |
| AU2012249301A1 (en) | 2011-04-29 | 2013-11-21 | Kinemed, Inc. | Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents |
| AU2012280474A1 (en) | 2011-07-01 | 2014-01-16 | Bayer Intellectual Property Gmbh | Relaxin fusion polypeptides and uses thereof |
| AU2012283235A1 (en) | 2011-07-08 | 2014-01-09 | Bayer Intellectual Property Gmbh | Fusion proteins releasing Relaxin and uses thereof |
| TW201806968A (zh) | 2011-10-18 | 2018-03-01 | 艾利倫治療公司 | 擬肽巨環化合物 |
| KR101895047B1 (ko) | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
| HK1205454A1 (en) | 2012-02-15 | 2015-12-18 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
| CN104302408B (zh) | 2012-02-27 | 2016-12-14 | 阿穆尼克斯运营公司 | Xten缀合组合物和制造其的方法 |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| US9273093B2 (en) | 2012-10-11 | 2016-03-01 | Protagonist Therapeutics, Inc. | α4β7 peptide dimer antagonists |
| WO2014071241A1 (en) | 2012-11-01 | 2014-05-08 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
| EP2992008B1 (en) | 2013-05-02 | 2019-04-10 | GlaxoSmithKline Intellectual Property Development Limited | Therapeutic peptides |
| DK3019533T3 (da) | 2013-07-11 | 2020-03-23 | Scripps Research Inst | Dobbeltspiraliserede immunoglobulinfusionproteiner og sammensætninger deraf |
| WO2015038938A1 (en) | 2013-09-13 | 2015-03-19 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| AR103242A1 (es) | 2015-01-09 | 2017-04-26 | Lilly Co Eli | Compuestos co-agonistas de gip y glp-1 |
| MA41794A (fr) | 2015-03-18 | 2018-01-23 | The California Institute For Biomedical Res | Agents thérapeutiques modifiés et compositions associées |
| WO2017007612A1 (en) | 2015-07-07 | 2017-01-12 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| WO2017024317A2 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Methods to induce targeted protein degradation through bifunctional molecules |
| CA2994969A1 (en) | 2015-08-06 | 2017-02-09 | Dana-Farber Cancer Institute, Inc. | Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses |
| US9809603B1 (en) | 2015-08-18 | 2017-11-07 | Deuterx, Llc | Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same |
| US20190216893A1 (en) | 2016-06-03 | 2019-07-18 | The Scripps Research Institute | Compositions and methods of modulating immune response |
| IL325835A (en) | 2016-12-23 | 2026-03-01 | Univ Yale | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides |
| EP4119552A1 (en) | 2017-02-08 | 2023-01-18 | Dana-Farber Cancer Institute, Inc. | Regulating chimeric antigen receptors |
| US12023385B2 (en) | 2017-02-08 | 2024-07-02 | Dana-Farber Cancer Institute, Inc. | Tunable endogenous protein degradation with heterobifunctional compounds |
| US20200199102A1 (en) | 2017-04-05 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| JP7472026B2 (ja) | 2018-02-23 | 2024-04-22 | デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド | 選択的なタンパク質分解を誘導するための低分子およびその使用法 |
| WO2019203645A1 (en) | 2018-04-19 | 2019-10-24 | Stichting Vu | Protein macrocyclization |
| ES3068975T3 (en) | 2018-07-23 | 2026-06-03 | Lilly Co Eli | Gip/glp1 co-agonist compounds |
| EP3864030A4 (en) | 2018-10-12 | 2022-09-21 | The Scripps Research Institute | Compounds and methods for dcaf-mediated protein degradation |
| EP4069726A4 (en) | 2019-12-04 | 2024-03-20 | The Scripps Research Institute | GLP2 RECEPTOR AGONISTS AND METHOD OF USE |
| AU2022289610A1 (en) | 2021-06-09 | 2024-01-25 | The Scripps Research Institute | Long-acting dual gip/glp-1 peptide conjugates and methods of use |
-
2020
- 2020-12-03 EP EP20896436.1A patent/EP4069726A4/en active Pending
- 2020-12-03 AU AU2020397917A patent/AU2020397917A1/en active Pending
- 2020-12-03 KR KR1020227022195A patent/KR20220110244A/ko active Pending
- 2020-12-03 JP JP2022532862A patent/JP7834640B2/ja active Active
- 2020-12-03 KR KR1020227022197A patent/KR20220123648A/ko active Pending
- 2020-12-03 EP EP20896451.0A patent/EP4069274A4/en active Pending
- 2020-12-03 WO PCT/US2020/063130 patent/WO2021113524A2/en not_active Ceased
- 2020-12-03 CA CA3163522A patent/CA3163522A1/en active Pending
- 2020-12-03 IL IL293522A patent/IL293522A/en unknown
- 2020-12-03 US US17/782,560 patent/US20230057847A1/en active Pending
- 2020-12-03 CA CA3163507A patent/CA3163507A1/en active Pending
- 2020-12-03 CN CN202080095675.2A patent/CN115052615A/zh active Pending
- 2020-12-03 MX MX2022006732A patent/MX2022006732A/es unknown
- 2020-12-03 IL IL293460A patent/IL293460A/en unknown
- 2020-12-03 JP JP2022531616A patent/JP7691421B2/ja active Active
- 2020-12-03 MX MX2022006861A patent/MX2022006861A/es unknown
- 2020-12-03 AU AU2020397918A patent/AU2020397918A1/en active Pending
- 2020-12-03 US US17/782,573 patent/US12583900B2/en active Active
- 2020-12-03 WO PCT/US2020/063149 patent/WO2021113535A1/en not_active Ceased
- 2020-12-03 CN CN202080095661.0A patent/CN115052886B/zh active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060252916A1 (en) * | 2002-06-04 | 2006-11-09 | Eli Lilly And Company | Modified glucagon-like peptide-1 analogs |
| US20170260248A1 (en) * | 2010-07-09 | 2017-09-14 | Dana-Farber Cancer Institute, Inc. | Stabilized insulinotropic peptides and methods of use |
| US20160317623A1 (en) * | 2013-12-18 | 2016-11-03 | The California Institute For Biomedical Research | Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof |
| CN106456589A (zh) * | 2013-12-18 | 2017-02-22 | 加州生物医学研究所 | 修饰的治疗剂、订合的肽脂质缀合物及其组合物 |
| CN107921098A (zh) * | 2015-06-17 | 2018-04-17 | 加州生物医学研究所 | 修饰的治疗剂及其组合物 |
| CN110036022A (zh) * | 2016-10-27 | 2019-07-19 | 詹森药业有限公司 | 作为神经肽y受体的调节剂的抗体-偶联的环状肽酪氨酸酪氨酸化合物 |
| WO2019207505A1 (en) * | 2018-04-25 | 2019-10-31 | Janssen Pharmaceutica Nv | Glucagon like peptide 1 (glp-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof |
Non-Patent Citations (2)
| Title |
|---|
| PENG-YU YANG等: "Engineering a long-acting, potent GLP-1 analog for microstructure-based transdermal delivery", PNAS, vol. 113, no. 15, 18 February 2016 (2016-02-18), pages 4140 - 4145 * |
| PENG-YU YANG等: "Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models", J. MED. CHEM, vol. 61, no. 7, 12 March 2018 (2018-03-12), pages 3218 - 3223 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025073222A1 (zh) * | 2023-10-07 | 2025-04-10 | 深圳湾实验室 | Glp-1r/gipr/gcgr三重激动剂类似物及其用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220110244A (ko) | 2022-08-05 |
| CA3163522A1 (en) | 2021-06-10 |
| JP2023504184A (ja) | 2023-02-01 |
| CN115052886A (zh) | 2022-09-13 |
| CA3163507A1 (en) | 2021-06-10 |
| EP4069726A4 (en) | 2024-03-20 |
| US12583900B2 (en) | 2026-03-24 |
| US20230057847A1 (en) | 2023-02-23 |
| AU2020397917A1 (en) | 2022-06-23 |
| US20230071371A1 (en) | 2023-03-09 |
| WO2021113524A2 (en) | 2021-06-10 |
| MX2022006861A (es) | 2022-07-11 |
| KR20220123648A (ko) | 2022-09-08 |
| WO2021113524A3 (en) | 2021-07-15 |
| JP2023513658A (ja) | 2023-04-03 |
| EP4069726A2 (en) | 2022-10-12 |
| IL293460A (en) | 2022-07-01 |
| JP7691421B2 (ja) | 2025-06-11 |
| AU2020397918A1 (en) | 2022-06-23 |
| WO2021113535A1 (en) | 2021-06-10 |
| JP7834640B2 (ja) | 2026-03-24 |
| EP4069274A1 (en) | 2022-10-12 |
| IL293522A (en) | 2022-08-01 |
| CN115052886B (zh) | 2025-09-09 |
| EP4069274A4 (en) | 2024-04-10 |
| MX2022006732A (es) | 2022-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7834640B2 (ja) | ペプチドコンジュゲートおよび使用方法 | |
| US12083164B2 (en) | Amylin analogues | |
| KR102505628B1 (ko) | 글루카곤 및 glp-1 수용체의 장기-작용성 공-효능제 | |
| CN107073130B (zh) | 脂肪酸及其在与生物分子缀合中的用途 | |
| CN117794946A (zh) | 长效双重gip/glp-1肽缀合物及使用方法 | |
| US10766939B2 (en) | Amylin analogues | |
| WO2013186240A2 (en) | Exendin-4 peptide analogues | |
| PH12015500688B1 (en) | Exendin-4 derivatives as dual glp1/glucagon agonists | |
| EP3430033A1 (en) | Insulin-incretin conjugates | |
| JP2022023179A (ja) | アシル化オキシントモジュリンペプチド類似体 | |
| KR20240082386A (ko) | 글루카곤 및 ampk 활성화제의 공액체 | |
| HK40108093A (en) | Long-acting dual gip/glp-1 peptide conjugates and methods of use | |
| WO2026073159A1 (en) | Triple gip/glp-1/glucagon peptide conjugates and methods of use | |
| WO2025184552A2 (en) | Dual gip/glp-1 peptide conjugates and methods of use | |
| WO2025242218A1 (zh) | 一种多肽激动剂,其制备方法及医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |